Target intelligence / Profile preview

Enterovirus non-structural protein 2C (2C)

Target
2C
Molecular classification
Enzyme, AAA+ ATPase, Helicase Superfamily 3 (SF3), RNA-binding protein
01

Overview

Enterovirus non-structural protein 2C is a highly conserved, multifunctional enzyme essential for the replication cycle of viruses within the Enterovirus genus, including poliovirus, enterovirus A71, and coxsackievirus [1, 3, 9]. Belonging to the AAA+ ATPase superfamily and Helicase Superfamily 3 (SF3), 2C coordinates critical processes such as viral RNA synthesis, the remodeling of host membranes into replication organelles, and the encapsidation of the viral genome [3, 11]. Because it is among the most conserved proteins across diverse enterovirus species, it is a primary target for the development of broad-spectrum, pan-enteroviral therapeutics [1, 9]. Several repurposed drugs, such as the (S)-enantiomer of fluoxetine and the anesthetic dibucaine, have been identified as 2C inhibitors that act by binding to allosteric sites to disrupt the protein's enzymatic activity or its ability to form functional hexamers [2, 5, 8]. However, therapeutic challenges remain, particularly the rapid emergence of escape mutants and the fact that many current inhibitors show activity against only specific species (e.g., EV-B and EV-D) rather than the entire genus [2, 4, 7].

Other names
Enterovirus 2C AAA+ ATPaseP2C2C protein2C ATPase2C helicaseNon-structural protein 2C
02

Mechanism of action

Inhibition of ATP hydrolysis through allosteric binding, disruption of hexameric oligomerization, or interference with RNA binding and membrane association.

03

Biological functions

Viral RNA replicationViral genome encapsidationMembrane remodelingATPase activityRNA chaperoningViral morphogenesisImmune evasion
04

Disease associations

InfectionHand, foot, and mouth diseasePoliomyelitisHerpanginaEncephalitisMyocarditisAseptic meningitisAcute flaccid myelitisRespiratory infection
05

Safety considerations

Rapid development of drug resistance mutations in the 2C coding regionSpecies-specific sensitivity differences (e.g., fluoxetine is ineffective against EV-A and EV-C species)Potential off-target inhibition of host cell AAA+ ATPases
06

Interacting drugs

Fluoxetine

9 more in the full profile.

07

Biomarkers

Viral RNA loadViral 2C protein expression

Beyond the preview

Go deeper on Enterovirus non-structural protein 2C (2C).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enterovirus non-structural protein 2C (2C).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call